Failure of fast track approval for cabo for prostate cancer for COMET-1 shaved 40% off this stock overnight. The product is targeted for 3rd line anyway and is on the market so know to be safe and relatively well tolerated. A 6 month delay in approval doesn't change the potential of the molecule. Plus the data melanoma/Roche data..solid buy.